Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$4.25 - $10.71 $189,554 - $477,676
-44,601 Reduced 31.74%
95,899 $989,000
Q3 2023

Nov 13, 2023

SELL
$7.86 - $10.08 $21,041 - $26,984
-2,677 Reduced 1.87%
140,500 $1.1 Million
Q2 2023

Aug 14, 2023

BUY
$8.7 - $13.28 $1.25 Million - $1.9 Million
143,177 New
143,177 $1.43 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Globeflex Capital L P Portfolio

Follow Globeflex Capital L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Globeflex Capital L P, based on Form 13F filings with the SEC.

News

Stay updated on Globeflex Capital L P with notifications on news.